TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Oncopeptides AB ( (SE:ONCO) ) has issued an update.
Oncopeptides AB announced the publication of three case reports in the Journal of Cancer Research and Clinical Oncology, showcasing long-lasting responses to their drug Pepaxti in patients with relapsed or refractory multiple myeloma. These findings, derived from the OCEAN and HORIZON studies, highlight Pepaxti’s potential as a significant treatment option for patients who may not have access to novel immunotherapies, demonstrating its ability to deliver sustained benefits and durable remissions in real-world settings.
The most recent analyst rating on (SE:ONCO) stock is a Hold with a SEK5.00 price target. To see the full list of analyst forecasts on Oncopeptides AB stock, see the SE:ONCO Stock Forecast page.
More about Oncopeptides AB
Oncopeptides AB is a Swedish biotech company that specializes in the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. Utilizing its proprietary Peptide Drug Conjugate platform, the company develops compounds that selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is being commercialized in Europe and has partnership agreements in South Korea, the Middle East, and Africa. Oncopeptides is listed on Nasdaq Stockholm and operates in several European countries.
Average Trading Volume: 5,382,185
Technical Sentiment Signal: Buy
Current Market Cap: SEK1.33B
For an in-depth examination of ONCO stock, go to TipRanks’ Overview page.